Evidence-based Products

Study claim: Taking two capsules/day Xenadrine for six weeks may reduce percentage of body fat, fat mass and overall body weight in obese adults.

Published: Armstrong J, et al. The effect of commercial thermogenic weight loss supplement on body composition and energy expenditure in obese adults. JEPonline 2001 May;4(2):28-35.

Abstract: Researchers studied the effects of Xenadrine, an herbal preparation of 20mg ma huang, 85mg bitter orange, 40mg pantothenic acid, 105mg white willow bark extract, 50mg ginger root, 200mg guarana and a proprietary blend of L-Tyrosine, Acetyl L-carnitine, fisetin, magnesium phosphate and DMEA per each two-capsule dose. They tested the formula on resting energy expenditure (REE), blood chemistries and body composition. They randomly assigned five males and 15 females, all obese and ranging in age from 31 to 66 years of age, to take either Xenadrine or placebo for six weeks, while participating in an aerobic exercise program three times a week for 44 days.

The Xenadrine test subjects lost 524 per cent more total fat and 759 per cent more weight than the placebo group. They also gained 61 per cent more lean body mass without reducing their food intake.

Potential applications: Xenadrine is also available in an ephedra-free formula, both in capsule form and intended for overweight individuals with no other health conditions.

More info:
Cytodyne Technologies
PO Box 1421, Lakewood, New Jersey 08701
+1 888 298 6396

LipoSan Ultra
Study claim: 3g/daily LipoSan Ultra can effectively facilitate weight loss and help reduce body fat in overweight and mildly obese individuals.

Published: Schiller R, et al. A randomised, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. J Am Nutraceutical Assoc 2001 Spring;4(1):34-41.

Abstract: 59 overweight, mildly obese but otherwise healthy females with a history of daily dietary fat consumption greater than or equal to 30 per cent of total calories participated in this trial. They took either three capsules (divided into two 1.5g doses) of LipoSan Ultra or placebo twice daily for eight weeks, with no additional food modifications, restrictions or caloric reductions.

Mean weight, body mass index (BMI) and per cent body fat increased significantly in the placebo group compared with baseline measures. Within the treatment group, mean weight loss was 1kg and BMI also decreased. Significantly more subjects lost weight within the treatment group than within placebo (63 per cent and 17 per cent, respectively).

The researchers attributed LipoSan Ultra's efficacy to rapid solubility of approximately one minute, enabling it to emulsify and trap more dietary fat than regular chitosan.

Potential applications: LipoSan Ultra is a branded raw ingredient that can be used in capsule and tablet formulations, and possibly in chews and liquids for individuals trying to reduce their fat uptake.

More info:
Vanson Inc
8840 152 Avenue NE
Redmond, Washington 98052
+1 888 282 6766

Study claim: Supplemental Ocuvite can help lower the risk of developing advanced-stage age-related macular degeneration (AMD) and its associated vision loss by 25 per cent.

Published: A randomised, placebo-controlled clinical trial of high-dose supplementation with vitamins C and beta-carotene for age-related cataract and vision loss. Arch Ophthalmol 2001 Oct;119:1439-52.

Abstract: In this double-blind, Age-Related Eye Disease Study (AREDS), researchers studied 4,757 participants, 55 to 88 years old, in 11 US clinical centres for an average of 6.3 years. Participants were randomly assigned to take one of four treatments: zinc alone, antioxidants alone (500mg vitamin C, 400IU vitamin E and 15mg beta-carotene), a combination of antioxidants and zinc or placebo. Participants with more than a few small drusen, or pathological growths, took 80mg zinc (zinc oxide) tablets or placebo. Baseline and annual (starting at year 2) lens photographs were graded for the severity of lens opacities using the AREDS cataract grading scale.

Participants at high risk of developing AMD lowered their risk by 25 per cent when treated with Ocuvite. Those with intermediate AMD or advanced AMD in one eye saw a 19 per cent reduction in the risk of vision loss caused by AMD.

Potential applications: Ocuvite is available in tablets and intended for individuals in the intermediate stages of age-related macular degeneration.

More info:
Bausch & Lomb 1400 N. Goodman St.,
PO Box 450, Rochester, NY 14603-0450
+1 800 334 8815
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.